Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Rivastigmine Patch for Mild-to-Moderate Alzheimer’s

Fineline Cube Sep 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Belief BioMed Partners with Bayer’s AskBio to Explore New Gene Therapies

Fineline Cube Sep 26, 2024

Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a...

Company Deals

Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade

Fineline Cube Sep 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Policy / Regulatory

Beijing Authorities Launch Plan to Streamline Temporary Import of Urgently Needed Medical Drugs and Devices

Fineline Cube Sep 26, 2024

In a joint effort to streamline access to critical medical resources, the Beijing Municipal Medical...

Hospital Policy / Regulatory

Beijing Expands Medical Insurance Coverage to Include Anti-Aquaporin Antibody Testing and Advanced Heart Procedures

Fineline Cube Sep 26, 2024

The Beijing Municipal Medical Insurance Bureau and the Beijing Municipal Human Resources and Social Security...

Company Drug

Innovent Biologics Submits Market Approval Filing for Picankibart in Plaque Psoriasis to China’s CDE

Fineline Cube Sep 26, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has reportedly submitted...

Company Drug

Shanghai Haihe Pharmaceutical’s Oral Paclitaxel RMX3001 Wins NMPA Nod for Advanced Gastric Cancer

Fineline Cube Sep 26, 2024

Shanghai Haihe Pharmaceutical Co., Ltd from China and its South Korean partner Daehwa Pharmaceutical have...

Company Deals

TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China

Fineline Cube Sep 26, 2024

TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with...

Company Deals

Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal

Fineline Cube Sep 25, 2024

French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers...

Company Drug

Eli Lilly’s Kisunla Secures Market Approval in Japan for Early Symptomatic Alzheimer’s

Fineline Cube Sep 25, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that its Alzheimer’s disease (AD) treatment, Kisunla...

Company Drug

Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease

Fineline Cube Sep 25, 2024

Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...

Company

GSK Appoints Li Weidong as Vaccine Business Head for China

Fineline Cube Sep 25, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading pharmaceutical company based in the UK, has...

Company Deals

Beijing Bohui Innovation Biotechnology Ends Rabies Vaccine Partnership with BOAOVAX

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHA: 300318), a leading biopharmaceutical company in China,...

Company Deals

Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies

Fineline Cube Sep 25, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Elevation Oncology’s Claudin 18.2 Targeting ADC Earns FDA Fast Track Designation for Gastric Cancer

Fineline Cube Sep 25, 2024

Elevation Oncology, Inc. (NASDAQ: ELEV), a biopharmaceutical company based in the U.S., has announced that...

Company Deals

Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China,...

Company

InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025

Fineline Cube Sep 25, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...

Company Drug

China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA

Fineline Cube Sep 25, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...

Company Drug

Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications

Fineline Cube Sep 25, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...

Company Drug

Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial

Fineline Cube Sep 25, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Posts pagination

1 … 247 248 249 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.